Samuel Gooldy, MD
Family Medicine · New Hartford, NYNPI 1225187164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,803 and has fallen 64.5% since, to $640 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Merz North America, Inc.$1K
- AbbVie$1K
- Amgen$714
- AstraZeneca$667
- Amarin Pharma, Inc.$632
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$2403%
- Food & beverage$7,75297%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $1,481 |
| Merz North America, Inc. | 22 | $1,351 |
| AbbVie(2 entities) | 60 | $1,061 |
| Amgen(2 entities) | 38 | $714 |
| AstraZeneca | 43 | $667 |
| Amarin Pharma, Inc. | 33 | $632 |
| Lilly USA, LLC | 27 | $473 |
| Novo Nordisk | 17 | $300 |
| Novartis | 14 | $272 |
| Bausch Health US, LLC | 19 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $187 |
| Abbott | 7 | $156 |
| Pfizer | 8 | $127 |
| Boehringer Ingelheim | 5 | $85 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Tolmar, Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $24 |
| Mylan Specialty L.p. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$713
- TRELEGY ELLIPTA$247
- Repatha$125
- Vascepa$111
How this compares
$8,004 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $141,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $71,380 |
| JardianceEmpagliflozin | 58 | $55,571 |
| FarxigaDapagliflozin Propanediol | 42 | $51,523 |
| EliquisApixaban | 54 | $45,627 |
| JanuviaSitagliptin Phosphate | 21 | $27,617 |
| MounjaroTirzepatide | 22 | $24,142 |
| XareltoRivaroxaban | 28 | $20,349 |
| EntrestoSacubitril/Valsartan | 26 | $20,104 |
| VascepaIcosapent Ethyl | 26 | $13,744 |
| Rosuvastatin Calcium | 408 | $7,987 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,822 |
| Testosterone | 16 | $5,563 |
| Irbesartan | 176 | $4,751 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 95 | $4,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $300 | $141,26386 claims |
| GSKTrelegy Ellipta | $1,481 | $71,38095 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $85 | $61,39270 claims |
| AstraZenecaFarxiga | $667 | $51,52342 claims |
| PfizerEliquis | $127 | $45,62754 claims |
| Lilly USA, LLCMounjaro | $473 | $24,14222 claims |
| NovartisEntresto | $272 | $20,10426 claims |
| AbbVieSynthroid | $1,061 | $1,67045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in New Hartford
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.